PROK
PROKIDNEY CORP.
NASDAQ · Healthcare · Biotechnology · US
$1.30
−11.90%Year over year
Reported trailing growth
- Revenue
- +55.2%
- EBITDA
- -1.5%
- EBIT
- +2.4%
- EPS
- +0.0%
- Free cash flow
- -9.0%
- Operating cash flow
- -23.4%
Forward estimates
Based on analyst estimates
- Revenue
- +28.8%
- EBITDA
- +44.5%
- EPS
- +11.1%
Three-year CAGR
- Revenue
- +1075.0%
- EBITDA
- +8.8%
- EBIT
- +10.2%
- Net income
- -12.7%
- EPS
- +16.1%
- Free cash flow
- +13.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026